Novo Nordisk has a range of products relating to diabetes, haemostasis, obesity, growth and the menopause. Downloads of the Product Information for these products are available in this section.

Written principally for Healthcare Professionals, the Product Information documents provide prescribing information for each of our products. If you are not a Healthcare Professional, Product Information should be read/discussed in consultation with a Healthcare Professional.

To view these files you need to have Adobe Acrobat Reader installed. If you do not have Adobe Acrobat Reader you can download the software free of charge. Get Acrobat Reader


Novo Nordisk Pharmaceuticals Pty Ltd is experiencing strong demand for Ozempic® (semaglutide).  We understand this has resulted in intermittent availability at pharmacy.  We encourage patients to leave their prescription with their regular pharmacy or a preferred pharmacy, if possible. This will allow the pharmacist to order it for you and help you to get the medicines you need.  We are also strongly encouraging pharmacists to limit dispensing to only one month of medication at a time.  Our priority is to ensure people living with type 2 diabetes are able to access Ozempic® (semaglutide) and we are taking actions towards continued stable supply. 

A joint statement on the matter has been prepared by the following groups:

  • The Australian Medical Association (AMA)
  • The Royal Australian College of General Practitioners (RACGP)
  • The Australian Diabetes Society (ADS)
  • Diabetes Australia (DA)
  • Pharmaceutical Society of Australia (PSA)
  • National Pharmaceutical Services Association (NPSA)
  • Novo Nordisk Pharmaceuticals Pty Ltd